OneSource Specialty Pharma Limited has announced a governance tweak on its board, signaling a refined mix of independence and executive oversight. In a board meeting held on October 27, 2026, the company disclosed that Dr. Claudio Albrecht will shift his designation from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval. The move is being framed as a continuation of his service on the board, now under a non-executive, non-independent remit, rather than as a fresh appointment.
Dr. Albrecht arrives at Onesource with a storied track record in the global generics arena. He is the Co-Founder and Managing Partner of Albrecht, Prock & Partners AG, a Zug-based strategic advisory firm focused on pharmaceutical acquisitions and investments. Over more than three decades, he has steered top-line turnarounds and international expansion as CEO of Ratiopharm Group, Actavis Group and STADA AG, after starting his career at Sandoz and leading generics operations across the Netherlands, Germany, and the United States. During his tenure at Ratiopharm Group, he drove international growth and helped launch a biosimilars program. He also co-founded CoMeth and later steered Actavis through a major turnaround that culminated in a US$6 billion sale to Watson. His involvement in the leveraged buyout of STADA AG and development of a diabetes generics platform further underscores a robust track record in strategy and execution.
The company notes that Dr. Albrecht is not related to any other director and is not debarred from holding office by SEBI or other authorities. While the change in designation awaits shareholder approval, it reinforces Onesource’s board with a veteran outside perspective that blends strategic advisement with deep experience in global pharma markets. As governance continues to evolve, Onesource’s leadership appears intent on aligning its board credentials with its growth ambitions, while maintaining continuity through a director who remains liable to retirement by rotation under applicable law.